COVID-19 treatment by repurposing drugs until the vaccine is in sight.
Identifieur interne : 000915 ( 2020/Analysis ); précédent : 000914; suivant : 000916COVID-19 treatment by repurposing drugs until the vaccine is in sight.
Auteurs : Mrudula Phadke [Inde] ; Sujata Saunik [Inde]Source :
- Drug development research [ 1098-2299 ] ; 2020.
Abstract
Corona virus disease (COVID-19) has created pandemic in the world as declared by WHO on March 12, 2020. It is a viral disease caused by SARS-CoV 2 virus and has affected large populations in over 120 countries. There is no specific treatment available and management is empirical. Until such time that an effective vaccine is available for COVID-19 viral infection, one can repurpose known therapeutic drug molecules such as angiotensin receptor 2 blocker, a commonly used antihypertensive drug, to control COVID-19 virus from gaining entry into the host cell by blocking the angiotensin receptor. Clinical trials should also be undertaken to use statins, which are lipid-lowering drugs but have anti-inflammatory and immunomodulatory properties to prevent acute lung injury in COVID-19 infection.
DOI: 10.1002/ddr.21666
PubMed: 32227357
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000456
- to stream PubMed, to step Curation: 000456
- to stream PubMed, to step Checkpoint: 000726
- to stream Ncbi, to step Merge: 003634
- to stream Ncbi, to step Curation: 003634
- to stream Ncbi, to step Checkpoint: 003634
- to stream Main, to step Merge: 000915
- to stream Main, to step Curation: 000915
- to stream Main, to step Exploration: 000915
- to stream 2020, to step Extraction: 000915
Links to Exploration step
pubmed:32227357Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19 treatment by repurposing drugs until the vaccine is in sight.</title><author><name sortKey="Phadke, Mrudula" sort="Phadke, Mrudula" uniqKey="Phadke M" first="Mrudula" last="Phadke">Mrudula Phadke</name><affiliation wicri:level="1"><nlm:affiliation>NHM, Government of Maharashtra, UNICEF, Maharashtra University of Health Sciences, Nashik, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>NHM, Government of Maharashtra, UNICEF, Maharashtra University of Health Sciences, Nashik, Maharashtra</wicri:regionArea><wicri:noRegion>Maharashtra</wicri:noRegion></affiliation></author><author><name sortKey="Saunik, Sujata" sort="Saunik, Sujata" uniqKey="Saunik S" first="Sujata" last="Saunik">Sujata Saunik</name><affiliation wicri:level="1"><nlm:affiliation>NHM, Government of Maharashtra, UNICEF, Maharashtra University of Health Sciences, Nashik, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>NHM, Government of Maharashtra, UNICEF, Maharashtra University of Health Sciences, Nashik, Maharashtra</wicri:regionArea><wicri:noRegion>Maharashtra</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32227357</idno><idno type="pmid">32227357</idno><idno type="doi">10.1002/ddr.21666</idno><idno type="wicri:Area/PubMed/Corpus">000456</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000456</idno><idno type="wicri:Area/PubMed/Curation">000456</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000456</idno><idno type="wicri:Area/PubMed/Checkpoint">000726</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000726</idno><idno type="wicri:Area/Ncbi/Merge">003634</idno><idno type="wicri:Area/Ncbi/Curation">003634</idno><idno type="wicri:Area/Ncbi/Checkpoint">003634</idno><idno type="wicri:Area/Main/Merge">000915</idno><idno type="wicri:Area/Main/Curation">000915</idno><idno type="wicri:Area/Main/Exploration">000915</idno><idno type="wicri:Area/2020/Extraction">000915</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19 treatment by repurposing drugs until the vaccine is in sight.</title><author><name sortKey="Phadke, Mrudula" sort="Phadke, Mrudula" uniqKey="Phadke M" first="Mrudula" last="Phadke">Mrudula Phadke</name><affiliation wicri:level="1"><nlm:affiliation>NHM, Government of Maharashtra, UNICEF, Maharashtra University of Health Sciences, Nashik, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>NHM, Government of Maharashtra, UNICEF, Maharashtra University of Health Sciences, Nashik, Maharashtra</wicri:regionArea><wicri:noRegion>Maharashtra</wicri:noRegion></affiliation></author><author><name sortKey="Saunik, Sujata" sort="Saunik, Sujata" uniqKey="Saunik S" first="Sujata" last="Saunik">Sujata Saunik</name><affiliation wicri:level="1"><nlm:affiliation>NHM, Government of Maharashtra, UNICEF, Maharashtra University of Health Sciences, Nashik, Maharashtra, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>NHM, Government of Maharashtra, UNICEF, Maharashtra University of Health Sciences, Nashik, Maharashtra</wicri:regionArea><wicri:noRegion>Maharashtra</wicri:noRegion></affiliation></author></analytic><series><title level="j">Drug development research</title><idno type="eISSN">1098-2299</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Corona virus disease (COVID-19) has created pandemic in the world as declared by WHO on March 12, 2020. It is a viral disease caused by SARS-CoV 2 virus and has affected large populations in over 120 countries. There is no specific treatment available and management is empirical. Until such time that an effective vaccine is available for COVID-19 viral infection, one can repurpose known therapeutic drug molecules such as angiotensin receptor 2 blocker, a commonly used antihypertensive drug, to control COVID-19 virus from gaining entry into the host cell by blocking the angiotensin receptor. Clinical trials should also be undertaken to use statins, which are lipid-lowering drugs but have anti-inflammatory and immunomodulatory properties to prevent acute lung injury in COVID-19 infection.</div></front></TEI><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Phadke, Mrudula" sort="Phadke, Mrudula" uniqKey="Phadke M" first="Mrudula" last="Phadke">Mrudula Phadke</name></noRegion><name sortKey="Saunik, Sujata" sort="Saunik, Sujata" uniqKey="Saunik S" first="Sujata" last="Saunik">Sujata Saunik</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000915 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000915 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= pubmed:32227357
|texte= COVID-19 treatment by repurposing drugs until the vaccine is in sight.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:32227357" \
| HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |